secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001193125-24-174318
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Appoints David Johnson as COO effective July 1, 2024
----------------------------------------------------

- David Johnson named COO; previously Chief Commercial Officer at Global Blood Therapeutics.
- Annual base salary of $500,000; eligible for bonus up to 40% of base salary.
- Granted option to purchase 160,000 shares at $36.29, vesting over 4 years.
- Severance: 9 months salary without change in control; 12 months with change in control.
- Johnson also receives up to $10,000 reimbursement for legal fees related to offer letter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312524174318/0001193125-24-174318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312524174318/d799103d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-174318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer